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ABSTRACT 
Background:The etiologic role of human papillomaviruses (HPV) in oropharyngeal 
cancer (OPC) is well established. Nevertheless, information on survival differences by 
anatomic sub-site or treatment remains scarce, and it is still unclear the HPV-
relatedness definition with best diagnostic accuracy and prognostic value. 
Methods:We conducted a retrospective cohort study of all patients diagnosed with a 
primary OPCin four Catalonianhospitals from 1990 to 2013. Formalin-fixed, paraffin-
embedded cancer tissues were subjected to histopathological evaluation, DNA quality 
control, HPV-DNA detection, and p16INK4a/pRb/p53/Cyclin-D1 immunohistochemistry. 
HPV-DNA positive and a random sample of HPV-DNA negative cases were subjected 
toHPV-E6*I mRNA detection. Demographic, tobacco/alcohol use, clinical and follow-up 
data werecollected. Multivariate models were used to evaluate factors associated with 
HPV positivity as defined by four different HPV-relatedness definitions. Proportional-
hazards models were used to compare the risk of death and recurrence among HPV-
relatedand non-related OPC. 
Results:788 patients yielded a valid HPV-DNA result. The percentage of positive 
cases was 10.9%, 10.2%, 8.5% and 7.4% for p16INK4a, HPV-DNA, HPV-DNA/HPV-
E6*ImRNA, and HPV-DNA/p16INK4a, respectively. Being non-smoker or non-drinker 
wasconsistently associated across HPV-relatedness definitionswith HPV positivity. A 
suggestion of survival differences between anatomic sub-sites and treatments was 
observed. Double positivity for HPV-DNA/p16INK4ashowedstrongest diagnostic accuracy 
and prognostic value. 
Conclusions:Double positivity for HPV-DNA/p16INK4a, a test that can be easily 
implemented in the clinical practice, has optimal diagnostic accuracy and prognostic 
value.Our results have strong clinical implications for patients’ classification and 
handling and also suggest that not all the HPV-related OPC behave similarly. 
Keywords: Human papillomavirus; Oropharyngeal cancer; Prognosis markers; 
Diagnostic accuracy; Survival 
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RESEARCH HIGHLIGHTS 
 Six biomarkers of HPV-relatedness were assessed in788 oropharyngeal 
cancers 
 A low HPV attributable fraction in oropharyngeal cancer was observed  



























About a decade ago the International Agency for Research on Cancer (IARC) 
established high-risk Human papillomavirus 16(HPV16)as a cause of oropharyngeal  
carcinoma (OPC)[1]. Since then,increasing amount of information on the role of HPVs 
in OPC has been generated. The IARC estimates that approximately 29,000 new HPV-
related OPC cases occur every year, corresponding to 31% of the worldwide number of 
the overall incident OPCcases[2]. These estimates, as well as previous meta-analyses 
assessing the quantitative contribution of HPV, found high geographic heterogeneity in 
HPV-attributable fractions (AFs) of OPC, ranging from less than 20% in some world 
regions, 24% in Southern Europe to more than 60% in North America[3,4]. This low 
HPV-AF for OPC in Southern Europe has been recently confirmed in tworecent studies 
conducted by our group[5,6].  
HPV-related OPC differs at clinical, epidemiological and molecular level to OPC 
caused by classic risk factors (i.e. tobacco and alcohol)[7]. The consistent observation 
of improved survival and better response to treatment of HPV-related OPC has stirred 
up the state-of-the-art of their management. Indeed,several clinical trialsof de-
escalation treatmentsare under evaluation, aimingto achievebetter results with less 
treatment-associated comorbidities[8].However, the biological rationaleunderlyingthese 
strategies remains poorly understood,and most of schemes are extrapolated from 
HPV-negative OPC trials. Importantly, around 20% ofHPV-related patients still fail to 
treatment despite its good prognosis[7]. 
Diagnosis algorithms for HPV-related OPC are still under development. HPV-DNA 
detection alone is not sufficient to classify an OPC as HPV-driven since the presence 
of HPV-DNA could reflect a transient or non-related infection rather than a genuine 
HPV-driven oncogenic process[9-11]. Additionally, the detection of high cellular 
p16INK4a expressionby immunohistochemistry (IHC)is the most widely implemented 
technique in the clinical setting, but is not specific for HPV activity in these 
tumours[12,13]. Indeed, it has been demonstrated that patients with p16INK4ahigh 
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expressionbut HPV-DNA-negative OPC show a significantly less favourable survival 
than patients with p16INK4ahigh expression and HPV-DNA-positive tumours[14,15], 
indicating that p16INK4ahigh expression alone may not accurately classify HPV-related 
OPC patients.The combination of HPV-DNA detection and p16INK4a IHC is starting to be 
recommended to diagnose HPV-related OPCs[15]. Nevertheless, there is still limited 
information about the accuracy and prognostic value of this combination of biomarkers.  
It is imperative to identify the best HPV-relatedness definition for HPV causality and 
prognosis in OPC. This is a prerequisite to provide a sound approach to study 
differences in survival of HPV-related OPCby factors such as anatomical sub-
site[16,17]and bytreatment[18]. 
In an attempt to elucidate these gaps, weconducted astudy in OPC to assess the 
association of different HPV-relatedness definitions with patients’ overall survival 




Study design and population 
We designeda retrospective cohort study of all patients diagnosed with a primary OPC 
in four hospitals of Catalonia from 1990 to 2013 (Catalan Institute of Oncology-ICO-
Hospital Universitari de Bellvitge, Hospital de Sant Pau, Hospital del Mar and Hospital 
ParcTaulí).Protocols were approved by the ethics committee of each participating 
hospitals.  
Cancer cases were identified from medical records/pathology reports of the centres of 
origin. We included cases that fulfilled the following criteria: to be diagnosed with 
primary invasive cancer of the oropharynx (any histology; codes from the International 
Classification of Diseases for Oncology version 3: 
C01.9,C02.4,C05.1,C05.2,C09,C10,C14.2),and to have access to medical records on 
demographic and clinical information. 
From all eligible cases, we reviewed medical records of the patients and accessed 
information on demographics, smoking and alcohol consumption, clinical and follow-up 
data; andformalin-fixed paraffin embedded (FFPE) tumour samples from the diagnosis 
previous to treatment when available. 
In order to assess potential carryover HPV contamination at the local level, we 
additionally includeda set of control samples selected by local investigators (5% of the 
number of cases evaluated, corresponding to tissue samples of patients with 
diagnoses non- related with HPVprocessed in the same laboratory). 
FFPE Blocks Processing and Histopathological Evaluation 
All specimens processing was centralized at ICO. FFPE blocks were re-embedded 
whenever necessary. First and last sections were used for histopathological 
evaluationafter hematoxylin and eosin (H&E) staining. Two in-between sections were 
used for HPV-DNA testing, genotypingand E6*ImRNA detection; four additional slides 
were obtained to assess expression of cellular proteins by IHC. A block was classified 
as “adequate” for HPV testing if invasive cancer was observed in the two H&E stained 
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sections of the specimen. Pathology review was performed blind with respect to the 
original local diagnosis and followed a pre-established algorithm for diagnostic 
consensus involving three pathologists, as reported elsewhere[5]. Pathological 
classification was based on the World Health Organization pathological criteria for head 
and neck cancer[19]. 
FFPE blocks were processed under strict conditions of pre/post polymerase chain 
reaction (physical separation), and blank paraffin blocks were systematically tested in 
parallel to serve as sentinels for contamination as previously published[20]. 
HPV-DNA Detection and Genotyping 
The detailed methods used for HPV-DNA detection and genotyping have been 
reported elsewhere[21].Briefly, we used a PCR with the consensus primers SPF10 PCR 
and a DNA enzyme immunoassay (DEIA) to test for the presence of HPV-DNA. Virus 
genotyping was performed using reverse hybridization line probe assay (LiPA25_v1) 
on all samples testing positive for viral DNA, targeting 25 HPV types with different 
oncogenic risk (Laboratory Biomedical Products Rijswijk, The Netherlands). DNA 
quality was evaluated in all HPV-DNA negative samples by testing for thetubulin-β 
gene(21). All DEIA and LiPA25_v1 assays were performed at ICO. 
HPV-E6*I mRNA Detection 
All HPV-DNApositive samples underwent RNA extraction and HPV-E6*I mRNA 
detection at DKFZ, Heidelberg, Germany[22]. Briefly, the assays target a total of 20 
HPVs types. For each sample, type-specific E6*I mRNA reverse transcription 
quantitative PCR (RT-qPCR) was performed for all available HPVs types detected at 
the DNA level and additionally for HPV16. A random selection (10%) of HPV-
DNAnegative cancers was tested for HPV16-E6*I mRNA, and all of them were mRNA 
negative. Detection of housekeeping gene ubiquitin C mRNA was used for RNA quality 
control in all tested samples. 
Immunohistochemistry  
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Protein expression patterns were evaluated for p16INK4a, pRb, p53, and Cyclin-D1 in all 
samples, independently of HPV results. All IHC assays were all performed at Hospital 
General de L’Hospitalet, L’Hospitalet de Llobregat, Spain, under the manufacturer’s 
standards: Roche mtm Laboratories AG (Heidelberg, Germany) for p16INK4a, Vision 
Biosystems Novocastra (Newcastle, USA) for pRb, and Dako (Denmark) for p53 and 
Cyclin-D1. We used the predefined algorithm developed by Halec and colleagues[21]to 
determine the cutoff values for high vslow expression of pRb, p53, and Cyclin-D1. For 
p16INK4a, the intensityof nuclear and cytoplasmic staining within the tumourswas scored 
and those with a strong staining of>70% were considered p16INK4a high[23].The 
expected pattern for HPV-relatedcancers was high expression of p16INK4a and low 
expressionofthe other three cellular markers. 
Statistical Analyses 
Cancer samples having tested negative for both viral and human DNA were excluded 
from the analyses. In line with work from several authors[22], we established that in 
order to explore algorithms to classify an OPC as HPV-relatedwe needed to consider 
biomarkers of HPV infection (HPV-DNA detection), biomarkers of transcriptional activity 
of HPV oncogenes (HPV-E6*I mRNA), and surrogate biomarkers of HPV-related 
cellular transformation (p16INK4a, pRb, p53, andCyclin-D1). We used HPV-mRNA 
positivity as the gold standardforviral activity. We assumed that 90% of HPV-DNA 
negative cases not tested for E6*I mRNA were also mRNA negative.Weassessedthe 
accuracy of the four IHC, alone and combined, and of double positivity for HPV-
DNA/p16INK4aby estimating the sensitivity, specificity, odds ratios, and area under the 
receiver operating characteristic (ROC) curves (AUC), and compared the 
AUC.Descriptive, bivariate and unconditional logistic regression analyses were 
performed to identify independent factors (i.e. age, sex, tobacco-alcoholuse, clinical 
data) associated with HPV etiological involvement in OPC according to six different 
HPV-relatedness definitions: 1) HPV-DNA positivity; 2) p16INK4ahigh expression; 3) 
Double positivity for HPV-DNA/p16INK4a; 4) Double positivity for HPV-DNA/HPV-E6*I 
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mRNA; 5) Double positivity for HPV-DNA and (p16INK4a or HPV-E6*I mRNA)and 6) 
Triple positivity for HPV-DNA/HPV-E6*I mRNA/p16INK4a. Crude and adjusted odds 
ratios and their 95% confidence intervalswereestimated. Histological variables were not 
considered in multivariate analyses as previously described[21]. Survival time was 
calculated from the date of histological diagnosis to time of death for any cause (OS)or 
cancer recurrence (PFS). OS and PFS estimates were assessed upto 5 years. The 
cumulative probability of survival was estimated by Kaplan–Meier analysis. Survival 
curves were compared with the log-rank test, which was adjusted for multiple 
testingwhen making comparisons among the different HPV-relatedness definitions or 
when comparing treatments. Pairwise comparisons of 
survivalcurvesbetweengrouplevelswhen considering combinations of HPV-DNA 
detection and p16INK4a expression results or when examining the combined variableof 
HPV-status and tobacco use were also performed. All corrections were performed 
using the Benjamini-Hochberg procedure.Multivariate Cox’s proportional hazards 
models to explore the effect of the HPV status as a prognostic factor wereperformed, in 
all sites and stratified by anatomical sub-sites. Metastasic patients (stage IVc, 7th 




RESULTS   
Figure S1 describesthe workflow of the OPCtargeted cases, samples collected, 
processed, tested and finally included in the statistical analysis. A total of 1381 OPC 
cases were identified and included in the study, of which 555 (40.2%) had unavailable 
FFPE blocks at diagnosis. Cases provided by Sant Pau’s Hospital, diagnosed in older 
periods (1991-1994), located on the base of tongue (BOT) or patients who underwent a 
palliative treatment had lowest proportion of FFPE blocks available compared to other 
variable categories (data not shown).  
After pathology evaluation, samples from 802 OPC (58.1%) were tested for HPV-DNA.  
A total of 788 OPC samples yielded a valid DNA resultand were finally included in the 
analysis. HPV-DNA positivity was found in 80 (10.1%) samples. The percentage of 
HPV-relatedcases when considering only p16INK4ahigh expression was 10.9%, and it 
dropped to 8.5% and 7.4% respectively for double positive HPV-DNA/HPV-E6*I mRNA, 
and HPV-DNA/p16INK4a.Results of double positivity for HPV-DNA and (p16INK4a or HPV-
E6*I mRNA) were equivalent to those of double positivity for HPV-DNA/HPV-E6*I 
mRNA, and the same was observed between double positivity for HPV-DNA/p16INK4a 
and triple positivity for HPV-DNA/HPV-E6*I mRNA/p16INK4a. Thus, only four different 
HPV-relatedness definitions were further considered. The most common HPV type 
among HPV-DNA positive cases was HPV16 (67/80 cases, 83.8%), followed by HPV33 
(6.3%), HPV18 (2.5%) and HPV31, 51 and 58 (1.3% each). All HPVs were detected as 
single infections.In three cases (3.8%) the HPV present in the sample could not be 
genotyped. Positivity of HPV16 for cases double positive for HPV-DNA/HPV-
E6*ImRNA, and HPV-DNA/p16INK4awas 89.6% and 93.1%, respectively. 
Table S)1 shows the demographic and clinical characteristics of the 788 OPC patients 
included in the analysis, as well as the crude and adjusted measures of associations 
between those and double positivity for HPV DNA/p16INK4a. The equivalent results for 
HPV-DNA detection alone, p16INK4ahigh expression alone anddouble positivity for HPV-
DNA/HPV-E6*I mRNAare presented in table S2. Patients were mostly male (89.2%), 
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heavy smokers (75.6%) and drinkers (51.8%), with a locally advanced keratinizing 
grade 3 squamous cell carcinoma (SCC). Of note, 10 samples were defined as 
sarcomatoid SCC (3), undifferentiated carcinoma (4) and neuroendocrine carcinoma 
(3), and all of them were primary tumors. The tonsil was the most common anatomical 
sub-site (40.0%). After adjusting for significant co-variates, HPV-related patients were 
significantly more likely to be non-smokers and non-drinkers andto have a SCC of the 
tonsil, consistently across the four HPV-relatedness definitions analyzed. Association 
of HPV-positivity and female gender was observed in all univariate but none 
multivariate analyses.  
As described in table S3a, double positivity for HPV-DNA/p16INK4a was the biomarker 
combination that showed the highest AUC. Among surrogate biomarkers of HPV-
related cellular transformation alone, p16INK4a high expression was the one that showed 
best accuracy for diagnosis. Best accuracy parameters were observed in tonsillar 
cancers (table S3b). 
We examined the crudeOS and PFS of OPC patients based on Kaplan–Meier curves 
stratified by HPV positivity according to the four different HPV-relatedness 
definitions(figure 1 and figure S2, respectively). Double positivity for HPV-
DNA/p16INK4ashowedthe best prognostic value. Moreover, it classified better HPV-
related casesand showed improved five years OS and PFS irrespective of having an 
early or locally advanced OPC stage (figures S3 and S4).However, when 
examiningcrude OS of locally advanced OPC patients based on Kaplan–Meier curves 
stratified by standard treatments, better OS were not observed for 
patients’doublepositive for HPV-DNA/p16INK4atreated with bioradiotherapy (anti-EGFR 
concomitant with radiotherapy), as it was observed for other treatments (figure 2). 
Improved PFSwereobserved in patients’ double positive for HPV-DNA/p16INK4afor all 
treatment schemes herein evaluated (figure S5), although those were not statistically 
significant. We also analyzed crude OS of OPC patients according to the four possible 
combinations of HPV-DNA detection and p16INK4aexpression results. Pairwise analyses 
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showed that only patients double positive for HPV-DNA/p16INK4ahad a statistically better 
OS compared to any other combination of those biomarkers(figure 3). Importantly, 
HPV-DNA-negative/p16INK4apositive patientsdisplayed OS similar to HPV-DNA-
negative/p16INK4a-negativeor HPV-DNA-positive/p16INK4a-negative ones. 
Hazard ratios (HR)for death and for recurrence by HPV status according to the four 
HPV-relatedness definitions, after adjustment for age (only for death), tobacco 
use,stage and treatment,are presented in table 1.Statistically significant improvedOS 
and PFSamong patients with HPV-relatedOPCwere only observed in tonsillar 
cancer.Double positivity for HPV-DNA/p16INK4a was the biomarker with strongest 
prognostic value (OS adjusted HR 0.21, 95%CI 0.11-0.40). A statistically significant 
interaction between HPV status and tobacco use was observedin the multivariate Cox’s 
proportional hazards model for death for all anatomical sites. This interaction was not 
consistent across the four HPV-relatedness definitions and did not substantially 
improve the model. Thus, it was not further considered in the model. However, we 
explored the interaction further by creating a combined variable of HPV-status (as 
defined by double positivityfor HPV-DNA/p16INK4a) and tobacco use and examining the 
OS of each combination (figure S6), as well as stratifying the analyses by HPV status 
(tables S5a and S5b). Age was a prognostic factor for death in both HPV-positive and 
HPV-negative patients, consistently for all HPV-relatedness definitions. However, 
tobacco use was only a prognostic factor for death in HPV-positive (for all HPV-
relatedness definitions with the exception of double positivity for HPV-DNA/p16INK4a), 
but not in HPV-negative cases. On the other hand, stage and treatment scheme were 
prognostic factors in HPV-negative but not HPV-positive cases (with the exception of 
high expression of p16INK4a for treatment). Adjusted HRs for death were also examined 
for all cellularprotein biomarkers and their combinations (table S4).A better OS was 
observed for positivity to all markers, either individually or combined, except for low 




Mounting evidence supports the etiologic role of oncogenic HPVs in certain OPCs and 
the potential implications in the management of HPV-related patients. Our knowledge 
remains however incomplete regarding differences in prognosis by anatomic sub-site 
or treatment, or about the differential performance in terms of diagnostic accuracy and 
prognostic values between HPV-related biomarkers that can be easily implemented in 
the clinical setting. 
To the best of our knowledge, this study represents the first attempt to address jointly 
all these issues in a large retrospective series of unselected patients.In an era of de-
escalation clinical trials,this information is crucial in order to unequivocally identify 
patients who can really benefit from de-escalate protocolsand to avoidworsening their 
outcomes. 
The epidemiology of HPV-related OPC in our cohort differed in some aspects from 
what is observed in other high-income countries.HPV-AFs were slightly higherin 
women than in men, as has already been observed in other series[5], in contrast with 
what is observed in the United Statesin cohorts from the same time periods[24],. This 
discrepancy may reflect distinct temporal, geographical,and sociodemographic trendsin 
population exposure toboth tobaccouse and/or oral HPV infection, leading to arapid 
shift in the epidemiology of HPV-relatedOPC.  
We examined the HPV-diagnostic accuracy of several biomarkers with a previously 
validated robust and comprehensive methodology[5]. In line with our previous results[5] 
and a recent meta-analysis[15], doublepositivity for HPV-DNA/p16INK4ashowed higher 
AUCsthan any other combinations of biomarkers. Importantly, the double testing for 
HPV-DNA/p16INK4a can be easily implemented in the clinical setting. 
We examined the prognostic value of HPV-related biomarkers in OPC as defined by 
four different HPV-relatedness definitions. We found that HPV-positivity had stronger 
prognostic value than stage (7th edition TNM), consistently for all tests, since HPV-
relatedlocally advanced OPC patients had better OS and PFS thanstage I-II HPV-non-
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relatedones. However, double positivity for HPV-DNA/p16INK4a was the only biomarker 
showing the best prognostic value for HPV-relatedpatientsas also reported in a recent 
meta-analysis[25].  
When examining the prognostic value of double positivity for HPV-DNA/p16INK4a in 
locally advanced OPC patients by their standard treatments, we found that HPV-related 
OPCs showedimproved OS for all treatment schemes with the exception of those who 
underwent bioradiotherapy.  A recent study also suggested better outcomes in locally 
advanced HNSCC patients receiving concurrentcisplatin over cetuximab(anti-EGFR 
therapy)regardless of HPV/p16INK4astatus[26].Thesefindings have strong clinical 
implications becausecetuximabis being exploredas an alternative to cisplatin when 
given concurrently with radiotherapy as one main de-escalation strategies for HPV-
relatedOPC patientsaiming to reduce toxicities[8].However, our results should be 
interpreted with caution since the number of HPV-positive patients treated with 
bioradiotherapy was very small and thus underpowered to draw firm conclusions. 
Noteworthy, anti-EGFR therapies are not currently recommended for treatment of 
anogenital HPV-related cancer[27,28].Todate, the available evidencesupporting the 
use of anti-EGFR therapies in HPV-related OPC is therefore not conclusive; and we 
must wait for results of ongoing de-escalation clinical trials. 
We also wanted to elucidate the differences in OS and PFS according to HPV-status 
by anatomical sub-sites within the oropharynx. For all four HPV-relatedness definitions 
herein evaluated, HPV hadsignificant prognostic value only in tonsillarcarcinoma, and 
double positivity for HPV-DNA/p16INK4a was the biomarker with best prognostic value. 
This has also been reported for OS in a recent study of a large cohort of Danish 
patients[16]. However, this Danish study found equivalent results forBOT carcinoma, 
while in our case, although HPV-relatedBOT carcinoma displayed higher OS with 
lowest mortality observed for double positivity for HPV-DNA/p16INK4a, the results were 
not significantly different. This could be partially explained by the lower HPV 
prevalence in BOT carcinoma in our Spanish cohort (5.8%)as compared to the Danish 
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one (46%).On the other hand, our results on other locations than tonsil or BOT were in 
line with previous results from Sweden [17], where HPV-DNA and p16INK4astatus had 
no impact on clinical outcome in OPCs other than tonsil or BOT. However, the HRs of 
around 0.5 in these locations were in the same direction as those for tonsillar cancers, 
as it was observed for BOT cancers, despite their wide confidence intervals. Again, 
these results should be interpreted with caution due to small number of cases. 
When we examined adjusted HRs for death stratified by HPV status, we found 
differences between HPV-positive and negative OPC patients. The lack of prognostic 
advantage of non-smokers among HPV-negative patients could be partially explained 
by the limitation of self-reported data and warrant further research with biomarkers of 
tobacco use. On the other hand, the fact that stage was not a prognostic factor in HPV-
positive patients evidences the limitation of the 7th edition of TNM to accurately classify 
HPV-positive OPCs. 
Finally, when we evaluated the prognostic value of cellular biomarkers of protein 
expression alone or combined, none of them showed better HR than double positivity 
for HPV-DNA/p16INK4a, but we found better OS for p16INK4a overexpression alone than 
previous publications[29]. The discrepancy may be due to the differences in the 
difficulties for comparing cut-off points for p16INK4a expression between studies. 
Our study has several limitations. The retrospective nature of our cohort may have 
hampered the thorough characterization of the patients according to risk factors such 
as tobacco-alcohol use, since this kind of information could only be partially obtained 
from medical records. Also, paraffinblocks were not available at diagnosisfor an 
important number of cases, notably BOT carcinoma,alocation particularlymore difficult 
to biopsy, as well as forcases from older periods. For HPV-diagnostic accuracy 
analyses, we assumed that the 90% of HPV-DNA negative cases not tested for HPV-
E6*I mRNA were mRNA negative. Our classification of other sub-sites than tonsil or 
BOT comprised many different locations, including oropharynx specified or overlapping 
lesions that could include also tonsil and BOT.  In addition, we have a low rate of HPV-
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related OPC patients included in the analysis (i.e. Kaplan-Meir analysis by treatment), 
because HPV-related OPC AFs in our country is still low in comparison with other 
geographic regions like United States or Northern Europe.  
 
CONCLUSION  
Our findings from a large cohort of unselected OPC Spanish patients provide robust 
evidence that double positivity for HPV-DNA/p16INK4ahas optimal diagnostic accuracy 
and prognostic value as compared with a broad battery of HPV-related 
biomarkers.Noteworthy, this is a test that can be easily implemented and used in the 
clinical practice. Moreover, our results suggest that one of the main de-escalation 
treatment strategies for HPV-relatedOPC being currently evaluated in clinical trials 
(anti-EGFR/radiotherapy)may not be appropriate for HPV-related patients. Our results 
also suggest that there may be differences between OPC sub-sites regarding 
diagnostic accuracy and prognostic value of HPV-related biomarkers and thus, the 
need to address the management of the patients accordingly. Finally, our results have 
strong clinical implications as they contribute to a better classification of the patients to 
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Table 1.Hazardratios for deathandrecurrence for OPC patients, all sitesandstratifiedbyanatomicalsub-site (stageVIcpatientsareexcluded). 
FIVE-YEARS OVERALL SURVIVAL 
HPV 
BIOMARKER 
ALL SITES TONSIL BASE OF TONGUE OTHERS 
































691 / 426  








259 / 165  








151 / 98  






262 / 149  





DNA / mRNA 
Other 
+ / + 
 
704 / 434 








263 / 168  








152 / 99  






270 / 153  









685 / 422  








252 / 159  








152 / 99  






263 / 150  





DNA / p16 
Other 
+ / high 
 
712 / 439  








267 / 171  








155 / 101  






271 / 153  





FIVE-YEARS PROGRESSION-FREE SURVIVAL 
 
































691 / 194  








259 / 87  








151 / 37  






262 / 63  





DNA / mRNA 
Other 
+ / + 
 
704 / 197  








263 / 89 








152 / 37  






270 / 64  









685 / 193  








252 / 87  








152 / 38  






263 / 62  





DNA / p16 
Other 
+ / high 
 
712 / 200  








267 / 91  








155 / 38 






271 / 64  











Figure 1: 5 years Overall Survival by HPV status according to four different HPV-
relatedness definitions.  
Legend: Data on 5 years Overall Survival by HPV status according to four different 
HPV-relatedness definitions. Panel “a” showed Kaplan-Meier curve for HPV/DNA 
detection. Panel “b” showed Kaplan-Meier curve for HPV/DNA and HPV mRNA 
detection. Panel “c” showed Kaplan-Meier curve for p16INK4a detection. Panel “d” 
showed Kaplan-Meier curve for double positivity for HPV-DNA/p16INK4a. Panel “d”, 
double positivity for HPV-DNA/p16INK4a showed the best prognostic value, since it 
classified better HPV-related cases and showed improved 5 years OS. 
Figure 2: 5 years Overall Survival by standard treatment for locally advanced OPC 
patients (stages III, IVa and IVb) and HPV status according to double positivity for 
HPV-DNA/p16INK4a. 
Legend: Data on 5 years Overall Survival by standard treatment for locally advanced 
OPC patients (stages III, IVa and IVb) and HPV status double positivity for HPV-
DNA/p16INK4a. Panel “a” showed Kaplan-Meier curve for patients who underwent 
surgery with/without adjuvant chemo-radiotherapy. Panel “b” showed Kaplan-Meier 
curve for patients who underwent induction chemotherapy followed by chemo-
radiotherapy or bioradiotherapy. Panel “c” showed Kaplan-Meier curve for patients who 
underwent cisplatin-radiotherapy. Panel “d” showed Kaplan-Meier curve for patients 
who underwent cetuximab-radiotherapy. Improved OS was not observed on panel “d”. 
RT: radiotherapy; CT: chemotherapy; iCT: induction chemotherapy; bio-RT: 
bioradiotherapy (radiotherapy-cetuximab) 
Figure 3:  5 years Overall Survival by HPV-DNA detection and p16INK4ahigh 
expression. 
Legend: Pairwise analyses showed that only patients double positive for HPV-
DNA/p16INK4a had a statistically better OS compared to any other combination of those 
biomarkers. 
Table 1. Hazard ratios for death and recurrence for OPC patients, all sites and stratified by anatomical sub-site (stage IVc patients are excluded). 
FIVE-YEARS OVERALL SURVIVAL 
HPV 
BIOMARKER 
ALL SITES TONSIL BASE OF TONGUE OTHERS 
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Adjusted by age, tobacco consumption, stage and treatment. 
b
Adjusted by tobacco consumption, stage and treatment. 
 





Figure 2. 5 years Overall Survival by standard treatment for locally advanced OPSCC patients (stages III, IVa and IVb) and HPV status according to HPV-DNA 
positivity and p16
INK4a












Figure 1: 5 years Overall Survival by HPV status according to four different 
HPV-relatedness definitions.  
Legend: Data on 5 years Overall Survival by HPV status according to four 
different HPV-relatedness definitions. Panel “a” showed Kaplan-Meier curve for 
HPV/DNA detection. Panel “b” showed Kaplan-Meier curve for HPV/DNA and 
HPV mRNA detection. Panel “c” showed Kaplan-Meier curve for p16INK4a 
detection. Panel “d” showed Kaplan-Meier curve for double positivity for HPV-
DNA/p16INK4a. Panel “d”, double positivity for HPV-DNA/p16INK4a showed the 
best prognostic value, since it classified better HPV-related cases and showed 
improved 5 years OS. 
 
Figure 2: 5 years Overall Survival by standard treatment for locally advanced 
OPC patients (stages III, IVa and IVb) and HPV status according to double 
positivity for HPV-DNA/p16INK4a. 
Legend: Data on 5 years Overall Survival by standard treatment for locally 
advanced OPC patients (stages III, IVa and IVb) and HPV status double 
positivity for HPV-DNA/p16INK4a. Panel “a” showed Kaplan-Meier curve for 
patients who underwent surgery with/without adjuvant chemo-radiotherapy. 
Panel “b” showed Kaplan-Meier curve for patients who underwent induction 
chemotherapy followed by chemo-radiotherapy or bioradiotherapy. Panel “c” 
showed Kaplan-Meier curve for patients who underwent cisplatin-radiotherapy. 
Panel “d” showed Kaplan-Meier curve for patients who underwent cetuximab-
radiotherapy. Improved OS was not observed on panel “d”. 
RT: radiotherapy; CT: chemotherapy; iCT: induction chemotherapy; bio-RT: 
bioradiotherapy (radiotherapy-cetuximab) 
 
Figure 3:  5 years Overall Survival by HPV-DNA detection and p16INK4a high 
expression. 
Legend: Pairwise analyses showed that only patients double positive for HPV-




Table S1. Association of demographics and clinical characteristics of OPC patients included in 
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OPC: Oropharyngeal carcinoma; SD: Standard deviation; H: Hospital; SCC: Squamous cell carcinoma; BOT: Base of 












Includes SCC sarcomatoid, undifferentiated carcinoma and neuroendocrine carcinoma. 
*Not considered in the multivariate model as explained in Materials and Methods. 
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Adjusted by gender, sub-site, tobacco and alcohol consumption and stage. dIncludes symptomatic treatment (n=60). eIncludes SCC sarcomatoid, undifferentiated carcinoma and neuroendocrine carcinoma.  
*Not considered in the multivariate model as explained in Materials and Methods. 
 
 
Table S3a. Estimates of Odds Ratios, sensitivity, specificity, and area under the ROC curve for each cellular protein expression pattern, taking as gold standard 




Crude associations Sn/Sp/AUC† 
NO YES OR [95%CI] Sn [95%CI] Sp [95%CI] AUC [95%CI] p-value‡ 
HPV DNA/p16
INK4a 
           
– / low or high 721 9  Ref.         
+ / high 0 58 - - 86.6 [76.0-93.7] 100 [99.5-100] 0.93 [0.89-0.97]   - 
1 marker            
p16
INK4a
            
Low 691 9 Ref.         
High 28 58 159.0 [71.6-353.0] 86.6 [77.7-95.5] 96.1 [94.6-97.6] 0.91 [0.87-0.96] 0.515 
pRb            
High 276 6 Ref.         
Low 441 61 6.4 [2.7-14.9] 91.0 [83.5-98.6] 38.5 [34.9-42.1] 0.65 [0.61-0.69] <0.001  
CyD1            
High 618 16 Ref.         
Low 100 51 19.7 [10.8-35.9] 76.1 [65.2-87.1] 86.1 [83.5-88.7] 0.81 [0.76-0.86] <0.001 
p53            
High 375 0 Ref.         




 /pRb            
Other 691 14 Ref.         
High/Low 25 53 104.6 [51.4-213.1] 79.1 [68.6-89.6] 96.5 [95.1-97.9] 0.88 [0.83-0.93] 0.095 
p16
INK4a
 /p53            
Other 703 9 Ref.         
High/Low 14 58 323.6 [134.3-779.5] 86.6 [77.7-95.5] 98.0 [97-99.1] 0.92 [0.88-0.96] 0.743 
p16
INK4a
 /CyD1            
Other 699 23 Ref.         
High/Low 18 44 74.3 [37.3-147.8] 65.7 [53.6-77.8] 97.5 [96.3-98.7] 0.82 [0.76-0.87] 0.001 
pRb/CyD1            
Other 637 19 Ref.         
Low/Low 78 48 20.6 [11.5-36.9] 71.6 [60.1-83.2] 89.1 [86.7-91.5] 0.80 [0.75-0.86]  <0.001 
pRb/p53            
Other 507 6 Ref.         
Low/Low 209 91 24.7 [10.5-57.9] 91.0 [83.5-98.6] 70.8 [67.4-74.2] 0.81 [0.77-0.85]  <0.001 
CyD1/p53            
Other 667 16 Ref.         




 /pRb/CyD1            
Other 696 26 Ref.         
High/Low/Low 18 41 61.0 [30.9-120.2] 61.2 [48.8-73.6] 97.5 [96.3-98.7] 0.79 [0.73-0.85] <0.001 
p16
INK4a
 /pRb/p53            
Other 701 14 Ref.         
High/Low/Low 14 53 189.6 [85.9-418.4] 79.1 [68.6-89.6] 98.0 [97.0-99.1] 0.89 [0.84-0.94] 0.151 
p16
INK4a
 /CyD1/p53            
Other 704 23 Ref.         
High/Low/Low 11 44 122.4 [56.1-267.2] 65.7 [53.6-77.8] 98.5 [97.5-99.4] 0.82 [0.76-0.88] 0.002 
pRb/CyD1/p53            
Other 677 19          




 /pRb/CyD1/p53            
Other 702 26 Ref.         
High/Low/Low/Low 11 41 100.6 [46.5-217.8] 61.2 [48.8-73.6] 98.5 [97.5-99.4] 0.80 [0.74-0.86] <0.001 
Legend: OPC: Oropharygeal carcinoma; * Active HPV: "NO"-Includes DNA- OR [DNA+ and E6*I mRNA -], "YES"-Includes DNA+ and E6*I mRNA +;† Sn, sensitivity [%]; Sp, specificity [%]; AUC, area under the 









 alone, taking as gold standard 










         
Other 270 4        
+ / high 0 41 91.1 [78.8-97.5] 100 [98.6-100] 0.96 [0.91-0.99] - 
p16
INK4a
          
Low 254 4        
High 15 41 91.1 [78.8-97.5] 93.9 [90.7-96.8] 0.93 [0.88-0.97] 0.371 
Base of the tongue 
HPV DNA/p16
INK4a 
         
Other 157 4        
+ / high 0 10 71.4 [41.9-91.6] 100 [97.7-100] 0.86 [0.73-0.98] - 
p16
INK4a
          
Low 154 4        




         
Other 275 1        
+ / high 0 7 87.5 [47.3-99.7] 100 [98.7-100] 0.94 [0.82-1] - 
p16
INK4a
          
Low 265 1        
High 10 7 87.5 [47.3-99.7] 96.4 [93.4-98.2] 0.92 [0.80-1] 0.837 
Legend: OPC: Oropharygeal carcinoma; * Active HPV: "NO"-Includes DNA- OR [DNA+ and E6*I mRNA -], "YES"-Includes DNA+ and E6*I mRNA +;† Sn, sensitivity [%]; Sp, 
specificity [%]; AUC, area under the ROC curve; ‡ Z- test for equality of AUC compared to HPV & p16INK4a; OR, odds ratio; CI, confidence interval
Table S4. Hazard ratios for death for OPC patients 
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Table S5a. Hazard ratios for death in HPV-positive OPC patients, according to four different HPV relatedness definitions (stage IVc patients are excluded) 
FIVE-YEARS OVERALL SURVIVAL IN HPV-POSITIVE OPC PATIENTS 
RISK FACTORS 
DNA+ (n=79) p16+ (n=83) p16+ / DNA+ (n=58) DNA+ / mRNA+ (n=66) 
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0.27  (0.03-2.2) 
Treatment 
  RT 
  Surgery +/- CT/RT 
  CT-RT (cisplatin) 
  Bio-RT (cetuximab) 
  iCT + CT-RT/Bio-RT 













































































































Table S5b. Hazard ratios for death in HPV-negative OPC patients, according to four different HPV relatedness definitions (stage IVc patients are excluded) 
FIVE-YEARS OVERALL SURVIVAL IN HPV-NEGATIVE OPC PATIENTS 
RISK FACTORS 
DNA- (n=691) p16- (n=685) p16- / DNA- (n=712) DNA- / mRNA- (n=704) 
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Treatment 
  RT 
  Surgery +/- CT/RT 
  CT-RT (cisplatin) 
  Bio-RT (cetuximab) 
  iCT+CT-RT/Bio-RT 




































































































































Figure S5. 5 years Progression-free Survival by standard treatment for locally advanced OPC patients (stages III, IVa and IVb) and HPV status according 













Figure S6. 5 years Overall Survival by tobacco consumption and HPV status according to double positivity for HPV-DNA/p16
INK4a
 
 
 
 
 
